Reviews
Vol. 64 No. 2 (2012)
https://doi.org/10.4081/reumatismo.2012.113

Psoriatic arthritis: treatment strategies using biologic agents

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 30 April 2012
Published: 5 June 2012
1581
Views
1287
Downloads
Psoriatic disease, psoriatic arthritis, therapy, biologic drugs, anti-TNFα agents

Authors

S. D'Angelo
saldangelo@katamail.com
Lucania - San Carlo Hospital, Italy.
C. Palazzi
, Italy.
I. Olivieri
, Italy.
The traditional management of psoriatic arthritis (PsA) includes NSAIDs, corticosteroids and DMARDs. Advancement in the knowledge of the immunopathogenesis of PsA has been associated with the development of biologic agents which have revolutionized the management of the disease. Among biologics drugs, there are the 4 currently availablee anti-TNFα blocking agents (etanercept, infliximab, adalimumab and golimumab) which are more effective than traditional DMARDs on symptoms/signs of inflammation, quality of life, function, and in inhibiting the progression of the structural joint damage. Despite of the high cost, TNF inhibitors are costeffective on both the musculoskeletal and skin manifestations of psoriatic disease.

Downloads

Download data is not yet available.
S. D'Angelo, Lucania - San Carlo Hospital
Rheumatology Department

How to Cite



1.
Psoriatic arthritis: treatment strategies using biologic agents. Reumatismo [Internet]. 2012 Jun. 5 [cited 2026 Sep. 14];64(2):113-21. Available from: https://www.reumatismo.org/reuma/article/view/reumatismo.2012.113

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.